APA (7th ed.) Citation

E, B., MA, K., MP, K., I, L., N, J., N, D., . . . N, H. (2023). Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis. Pharmaceutical research, 40(11), 2653. https://doi.org/10.1007/s11095-023-03616-8

Chicago Style (17th ed.) Citation

E, Briggs, et al. "Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis." Pharmaceutical Research 40, no. 11 (2023): 2653. https://doi.org/10.1007/s11095-023-03616-8.

MLA (9th ed.) Citation

E, Briggs, et al. "Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis." Pharmaceutical Research, vol. 40, no. 11, 2023, p. 2653, https://doi.org/10.1007/s11095-023-03616-8.